230 clinical trials matched your search for Cancer. You can click one of the clinical trials below for more information, or click the Search Again button to enter different search text.

Search Again
Condition Study Title Investigator
Cancer A Study for Patients with Advanced Solid Tumors Using Study Drug BMS-986207 Shaheer Khan, DO
Cancer Tissue Repository For The Collection of Hematologic Samples Suzanne Lentzsch, MD
Cancer Collecting and growing patient tumor and blood cells from extra tissue to learn about cancer and test new drugs Matthew Ingham, MD
Cancer Molecular Analysis for Therapy Choice (MATCH) Richard Carvajal, MD
Cancer Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers Matthew Dallos, MD
Cancer Identification of Targets for Cancer Treatment Andrea Califano, PhD
Cancer Early Onset Malignancies Initiative (EOMI) Matthew Ingham, MD
Cancer Study of Atezolizumab in Alveolar Soft Part Sarcoma Gary Schwartz, MD
Cancer Study of Drug in Patients with Advanced Solid Malignancies and Lymphoma June Hou, MD
Cancer Study of Drug (MK-2118) in Patients with Solid Tumors or Lymphomas Matthew Ingham, MD
Cancer Clinical Trial Screening Tool to Address Cancer Health Disparities Katherine Crew, MD
Cancer A Study of MS-553 in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Nicole Lamanna, MD
Cancer Study of COM701 Alone and in Combination with Nivolumain in Patients with Advanced Solid Tumors (Breast Cancer/Ovarian Cancer/Lung Cancer) Benjamin Izar, MD
Cancer Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers Richard Carvajal, MD
Cancer LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) Antonio Fojo, MD, PhD
Cancer Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Mark Stein, MD
Cancer Study of IDE196 in Patients with Solid Tumors Richard Carvajal, MD
Cancer Study of Intratumorally Administered INT230-6 in Adult Subjects with Solid Tumors Matthew Ingham, MD
Cancer Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients (ages 18-21) Luca Szalontay, MD
Cancer Study of LN-145 in the Treatment of Squamous Cell Carcinoma of the Head & Neck or Non Small Cell Lung Cancer (NSCLC) Richard Carvajal, MD
Cancer Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices Grace Hillyer, EdD, MPH
Cancer LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkins Lymphoma Nicole Lamanna, MD
Cancer Study of ApricityOncology Smartphone Application Monitoring and Reporting Side Effects to their Nurses and Doctors Brian Henick, MD
Cancer Study of BA3011 in Subjects with Advanced Solid Tumors Matthew Ingham, MD
Cancer Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer Jennifer Amengual, MD
Cancer Study of AMG510 in Subjects with Advanced Solid Tumors Catherine Shu, MD
Cancer Combination Therapy in KRAS-mutated Advanced Malignancies (MEKiAUTO) Gulam Manji, MD, PhD
Cancer Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) Brian Henick, MD
Cancer A Study in Subjects With Advanced Cancer Richard Carvajal, MD
Cancer Safety Study of PBCAR0191 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia Ran Reshef, MD
Cancer TCR-engineered T Cells in Solid Tumors (ACTengine) Ran Reshef, MD
Cancer A Study of MORAb-202 in Participants With Selected Tumor Types June Hou, MD
Cancer Smartphone App for Cancer Medication Adherence Melissa Accordino, MD
Cancer Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Richard Carvajal, MD
Cancer Study of ST101 in Patients with Advanced Solid Tumors Fabio Iwamoto, MD
Cancer Study of RTX-240 in Adults with Relapsed/Refractory or Locally Advanced Solid Tumors Mark Stein, MD
Cancer Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers Benjamin Izar, MD
Cancer A First-in-Human Study of CDK-002 (exoSTING) in Subjects with Advanced/Metastatic Solid Tumors Matthew Ingham, MD
Cancer Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer Bret Taback, MD
Cancer A Study of ASP9801 in Patients With Advanced Metastatic Solid Tumors Matthew Ingham, MD
Cancer A Study of BMS-986340 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors Richard Carvajal, MD
Cancer Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Brian Henick, MD
Cancer COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors Benjamin Izar, MD
Cancer A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors Ryan Moy, MD
Cancer LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors Gulam Manji, MD, PhD
Cancer A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Cancer Benjamin Izar, MD
Cancer Study of AB928 in Combination with Other Therapies for Patients with Metastatic Colon Cancer (mCRC) Gulam Manji, MD, PhD
Cancer Study of BAY 1895344 in Combination with Chemotherapy for Patients with Metastatic Gastrointestinal Cancer Ryan Moy, MD
Cancer Study of Investigational Drug (RP-6306) in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of BAY 1895344 in Combination with Chemotherapy for Patients with Advanced Cancer Mark Stein, MD
Cancer Study of IV Contrast on Patients Going Through Image Guided Radiation Therapy (IGRT) for Abdominal and Pelvic Cancer David Horowitz, MD
Cancer Study of New Oral Anti-Cancer Drug (OACD) Dawn Hershman, MD
Cancer First-in-Human Study of DS-7300a in Subjects with Advanced Cancer Mark Stein, MD
Cancer Study of MPT-0118 Alone or in Combination with Keytruda in Patients with Advanced or Metastatic Cancer Shaheer Khan, DO
Cancer Study of Financial Navigator Addressing Cancer-Related Financial Hardship in Cancer Patients and Their Spouses Dawn Hershman, MD
Cancer Study of INCB106385 Alone or in Combination with INCMGA00012 in Patients with Advanced Cancer Mark Stein, MD
Cancer Study of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Divaya Bhutani, MD
Cancer Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer Benjamin Herzberg, MD
Cancer Study of Ulixertinib (BVD-523) for Patients with Advanced Cancer that Show Genetic Alterations Richard Carvajal, MD
Cancer Study of PF-07263689 Alone or in Combination with Sasanlimab for Patients with Advanced Cancer Brian Henick, MD
Cancer Study of IDE397 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of RP-6306 in Combination with Gemcitabine (Chemotherapy) for Patients with Advanced Solid Tumors Ryan Moy, MD
Cancer Study of CS5001 in Patients with Advanced Solid Tumors Richard Carvajal, MD
Cancer Study of RP-6306 in Combination with FOLFIRI in Patients with Advanced Solid Tumors (Colon, Esophageal, or GI Cancer) Ryan Moy, MD
Cancer ACCESS: Study of Donor Blood Stem Cell Transplant in Patients with Multiple Myeloma, Leukemia, or Lymphoma Ran Reshef, MD
Cancer Study of GSK3901961 and GSK3845097 in Patients with Synovial Sarcoma or Non-Small Cell Lung Cancer (NSCLC) Matthew Ingham, MD
Cancer Study of BT7480 in Patients with Advanced Cancer Richard Carvajal, MD
Cancer Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation Benjamin Herzberg, MD
Cancer Study of STK-012 Alone or in Combination with Pembrolizumab (KEYTRUDA) in Patients with Advanced Solid Tumors Benjamin Izar, MD
Breast Cancer A Study for Patients with Locally Advanced or Metastatic Breast Cancer Using Study Drug GDC-0077 Melissa Accordino, MD
Breast Cancer Study of the role of lymph node dissection in breast cancer patients after neoadjuvant chemotherapy Bret Taback, MD
Breast Cancer Study to Predict Your Therapeutic Response (I-SPY 2 Trial) Meghna Trivedi, MD
Breast Cancer Study Comparing Survival of Patients Monitored with Serum Tumor Marker Directed Disease Versus Usual Care in Metastatic Breast Cancer Melissa Accordino, MD
Breast Cancer ASPIRE: Study of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab Metastatic Breast Cancer Melissa Accordino, MD
Breast Cancer ARM: Axillary Reverse Mapping - Lymph Node Surgery Technique in Breast Cancer Bret Taback, MD
Breast Cancer Study of PMD-026 in Patients with Metastatic Breast Cancer with Expansion in Metastatic Triple Negative Breast Cancer Meghna Trivedi, MD
Breast Cancer Addinex-Opioid Dispenser for Post-Op Pain in Cancer Patients Dawn Hershman, MD
Breast Cancer MiChoice: Making Informed Choices on Incorporating Chemoprevention Into Care Katherine Crew, MD
Breast Cancer Study of Symptom Monitoring using Young, Empowered & Strong (YES) Web Portal for Breast Cancer Survivors Dawn Hershman, MD
Breast Cancer Study of Improving Patient-Centered Communication in Patients with Breast Cancer Bret Taback, MD
Breast Cancer Study of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple-Negative Breast Cancer Meghna Trivedi, MD
Breast Cancer Decreasing Chemotherapy for HER2 Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy Julia McGuinness, MD
Breast Cancer Study of T-DM1 in Combination with Tucatinib for Patients with HER2-Positive Breast Cancer Julia McGuinness, MD
Breast Cancer Intervention to Improve Medication Scheduling for Patients with Breast Cancer Dawn Hershman, MD
Breast Cancer Study of RLY-2608 in Patients with Breast Cancer Julia McGuinness, MD
Breast Cancer Study of Radiation Therapy Alone or in Combination With Olaparib for Patients with Inflammatory Breast Cancer (IBC) Eileen Connolly, MD, PhD
Breast Cancer Study of GLSI-100 in Female Patients with Breast Cancer Julia McGuinness, MD
Breast Cancer Study of Imprime PGG and Pembrolizumab (Keytruda) in Patients with Metastatic Breast Cancer (mBCA) Julia McGuinness, MD
Breast Cancer Study of Denosumab in Women with Breast Cancer who Carry the BRCA1 Mutation Katherine Crew, MD
Multiple Myeloma A study for patients with relapsed of refractory multiple myeloma using study drug KPT-330 Suzanne Lentzsch, MD
Multiple Myeloma Study of Drug in Subjects with Multiple Myeloma Suzanne Lentzsch, MD
Multiple Myeloma Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2) Ran Reshef, MD
Multiple Myeloma First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma Suzanne Lentzsch, MD
Multiple Myeloma Study of PBCAR269A in Participants With Relapsed/Refractory Multiple Myeloma Ran Reshef, MD
Multiple Myeloma Safety and Efficacy of Bb2121 (Ide-cel) Combinations in Patients with Multiple Myeloma (KarMMa-7) Ran Reshef, MD
Multiple Myeloma Study of Isatuximab in Patients with Multiple Myeloma or Lymphoma who are Recovering from Stem Cell Transplant Divaya Bhutani, MD
Multiple Myeloma Study of Daratumumab in Addition to Chemotherapy for Patients with Smoldering Multiple Myeloma (SMM) Rajshekhar Chakraborty, MD
Multiple Myeloma Study of VRd Followed by Cilta-cel vs. VRd Followed by Rd Therapy in Patients with Newly Diagnosed Multiple Myeloma Ran Reshef, MD
Skin Cancer Cemiplimab Survivorship Epidemiology (CASE) Study Richard Carvajal, MD
Skin Cancer Study of Cemiplimab in Cutaneous Squamous Cell Carcinoma Shaheer Khan, DO
Liver Cancer A 5-Year Study of the Natural History and Management of Patients with Hepatocellular Carcioma (A Type of Liver Cancer) Elizabeth Verna, MD
Lymphoma Study of Drug for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease Ran Reshef, MD
Lymphoma Study of Nivolumab Plus Standard Chemotherapy in Comparison to Brentuximab Vedotin Plus Standard Chemotherapy for Advanced Hodgkin Lymphoma Jennifer Amengual, MD
Lymphoma Study of Tazemetostat or Placebo with Lenalidomide plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma Jennifer Amengual, MD
Lymphoma Dose-escalation Safety Study of PBCAR19B in Participants With CD19-expressing Malignancies (Non Hodgkin Lymphoma) Ran Reshef, MD
Lymphoma Study of LOXO-305 in Patients with Mantle Cell Lymphoma (MCL) Andrew Lipsky, MD
Lymphoma Study of Isatuximab in Patients with Multiple Myeloma or Lymphoma who are Recovering from Stem Cell Transplant Divaya Bhutani, MD
Lymphoma Study of Venetoclax in Addition to Usual Treatment for Patients with Waldenstrm's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Divaya Bhutani, MD
Lymphoma Study of CC-486 (Oral Azacitidine) Alone or in Combination with Chemo in Participants with Diffuse Large B Cell Lymphoma (DLBCL) (Ages 75+) Jennifer Amengual, MD
Lymphoma Study of TAK-007 in Patients with Non-Hodgkin Lymphoma Ran Reshef, MD
Lymphoma Study of Duvelisib or Azacitidine in Addition to Chemotherapy in Patients with Peripheral T-Cell Lymphoma (PTCL) Jennifer Amengual, MD
Lymphoma Study of Pembrolizumab, Ibrutinib and Rituximab in Patients with Primary Central Nervous System Lymphoma (PCNSL) Fabio Iwamoto, MD
Lung Cancer Study of Study Drug JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer Catherine Shu, MD
Lung Cancer Study of Therapies in Participants with Resectable (removable) and Untreated Non-Small Cell Lung Cancer (NSCLC) Catherine Shu, MD
Lung Cancer Testing Whether the Use of Brain Scans Alone vs. Brain Scans Plus Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer Simon Cheng, MD, PhD
Lung Cancer Study of JNJ-93841937 Participants with Advanced Non-Small Cell Lung Cancer Catherine Shu, MD
Lung Cancer Study of Amivantamab and Carboplatin-Pemetrexed Therapy, versus Carboplatin-Pemetrexed, in Participants With Non-Small Cell Lung Cancer Catherine Shu, MD
Lung Cancer Study of Durvalumab with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1) Catherine Shu, MD
Lung Cancer Study of Combining Osimertinib with and without Ramucirumab in Non-Small Cell Lung Cancer (NSCLC) Catherine Shu, MD
Lung Cancer Tomivosertib With Anti-PD-(L)1 in Subjects With Non-Small Cell Lung Cancer (NSCLC) Brian Henick, MD
Lung Cancer Study of Osimertinib (TAGRISSOTM) in Non-Small Cell Lung Cancer (NeoADAURA) Patients Catherine Shu, MD
Lung Cancer Study of Atezolizumab and Tiragolumab Alone or in Combination with Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC) Catherine Shu, MD
Lung Cancer Study in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) whose Disease has Gotten Worse After Osermitinib Treatment Catherine Shu, MD
Lung Cancer Study of Capmatinib for Patients with Non-Small Cell Lung Cancer (NSCLC) Catherine Shu, MD
Lung Cancer Study of Pembrolizumab Alone or in Combination with Chemotherapy in Older Patients with Non-Small Cell Lung Cancer Catherine Shu, MD
Lung Cancer Liver-Directed Radiotherapy Along with Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Liver Metastases Brian Henick, MD
Lung Cancer Study of Berzosertib Compared to Chemotherapy for Patients with Non-Small Cell Lung Cancer Benjamin Herzberg, MD
Gynecologic Cancer Study of REGN4018 Alone or in Combination with Cemiplimab in Patients with Ovarian Cancer June Hou, MD
Solid Tumors Study of Safety of New Investigational Study Drug Alone and with Nivolumab in Advanced Solid Tumors Mark Stein, MD
Solid Tumors Study of Drug Alone and In Combination with Nivolumab in Advanced Solid Tumors Richard Carvajal, MD
Solid Tumors Study of Drug PLX2853 in Subjects with Advanced Cancer Richard Carvajal, MD
Solid Tumors Study of ASTX029 in Subjects With Advanced Solid Tumors Ryan Moy, MD
Solid Tumors Feasibility, Safety, and Activity Study of BPX-601 in Subjects With Previously Treated Advanced Solid Tumors Mark Stein, MD
Solid Tumors Study of ASTX295 in Patients With Solid Tumors Gary Schwartz, MD
Solid Tumors A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Mark Stein, MD
Pancreatic Cancer The Cancer of the Pancreas Screening-5 Study (CAPS5 Study) Fay Kastrinos, MD
Pancreatic Cancer Study of Multiple Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Gulam Manji, MD, PhD
Pancreatic Cancer Study of Stimulation with Bethanechol in Pancreatic Adenocarcinoma Prior to Surgery Susan Bates, MD
Pancreatic Cancer Precision Oncology in Advanced Pancreatic Cancer Gulam Manji, MD, PhD
Pancreatic Cancer Chemo4METPANC: Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Motixafortide, and Cemiplimab in Pancreas Adenocarcinoma Gulam Manji, MD, PhD
Pancreatic Cancer Registry Study to Evaluate the Nanoknife System in Treating Stage 3 Pancreatic Adenocarcinoma Michael Kluger, MD, MPH
Pancreatic Cancer Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for Locally Advanced Pancreatic Cancer (TIGeR-PaC) Susan Bates, MD
Pancreatic Cancer Study of Bethanechol in Combination with Chemotherapy for Patients with Pancreatic Cancer Susan Bates, MD
Leukemia Study of Experimental Drug in Patients with Hematological Malignancies (Blood Cancers) Joseph Jurcic, MD
Leukemia Study of Bendamustine/Rituximab Induction Followed by Venetoclax and Rituximab Consolidation for Treatment of Chronic Lymphocytic Leukemia Nicole Lamanna, MD
Leukemia Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Joseph Jurcic, MD
Leukemia Study of Nivolumab in Combination with 5-Azacytidine in Acute Myeloid Leukemia (AML) - Children and Adults Age 1 to 30 Nobuko Hijiya, MD
Leukemia A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy Amer Assal, MD
Leukemia A Study of CYNK-001 in Adults with Newly Diagnosed Acute Myeloid Leukemia Joseph Jurcic, MD
Leukemia Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE) Joseph Jurcic, MD
Leukemia Study of Panzyga in Primary Infection Prophylaxis (Prevention) in Patients with Chronic Lymphocytic Leukemia (PRO-SID) Nicole Lamanna, MD
Leukemia A Study of GFH009 in Patients With Hematologic Malignancies Andrew Lipsky, MD
Leukemia Study of BGB-11417 in Patients with Leukemia Nicole Lamanna, MD
Leukemia Study of CGT9486 in Patients with Advanced Systemic Mastocytosis (AdvSM) Mark Heaney, MD, PhD
Leukemia Study for Patients with Chronic Lymphocytic Leukemia (CLL) who are Currently Receiving Treatment with Venetoclax Nicole Lamanna, MD
Leukemia Study of TSC 100 & TSC 101 in Patients with Leukemia Undergoing Haploidentical Allogeneic Blood Stem Cell Transplantation (HCT) Ran Reshef, MD
Leukemia Study of Fedratinib in Combination with Chemotherapy in Patients with Myeloproliferative Neoplasm (MPN) in Accelerated and Blast Phase Joseph Jurcic, MD
Leukemia Study of Pirtobrutinib (LOXO-305) Alone or in Combination With Chemotherapy in Patients with Chronic Lymphocytic Leukemia (CLL) Nicole Lamanna, MD
Leukemia Study of TL-895 Alone or in Combination with KRT-232 for Patients with Myelofibrosis (MF) Mark Heaney, MD, PhD
Leukemia Study of Venetoclax and Azacitidine After Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Amer Assal, MD
Leukemia Study of Polatuzumab Vedotin in Combination with Chemotherapy in Subjectswith Richter's Transformation Andrew Lipsky, MD
Bladder Cancer ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder Christopher Anderson, MD
Bladder Cancer Study of Intravesical Cabazitaxel, Gemcitabine and Cisplatin (CGC) in the Treatment of Urothelial Carcinoma (Bladder Cancer) Joel DeCastro, MD, MPH
Bladder Cancer First-in-Human Study of PF-07225570 Alone or in Combination with Sasanlimab for Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Joel DeCastro, MD, MPH
Gastrointestinal Study of Standard Chemotherapy Alone or Combined with Atezolizumab for Patients with Stage III Colon Cancer Karie D. Runcie, MD
Gastrointestinal Study of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer (MORPHEUS - CRC) Gulam Manji, MD, PhD
Gastrointestinal Solutions for Celiac Study Peter Green, MD
Gastrointestinal Study of RO7198457 for Patients Who Have Had Surgery for Stage II and Stage III Colon Cancer Karie D. Runcie, MD
Prostate Cancer IRONMAN: International Registry for Men with Advanced Prostate Cancer Mark Stein, MD
Prostate Cancer Study of androgen deprivation therapy followed by chemoimmunotherpy for newly metastatic hormone-sensitive prostate cancer (mHSPC) Mark Stein, MD
Prostate Cancer Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer Mark Stein, MD
Prostate Cancer Study of BMS-986218 + Degarelix Acetate vs. Degarelix Acetate Alone in Men with Prostate Cancer Karie D. Runcie, MD
Prostate Cancer Study of Abiraterone Acetate, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer Mark Stein, MD
Prostate Cancer PLX2853 with Abiraterone Acetate, Prednisone, and Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Mark Stein, MD
Prostate Cancer Study of ADXS-504 in Patients with Prostate Cancer Mark Stein, MD
Prostate Cancer Study of JNJ-75229414 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Mark Stein, MD
Prostate Cancer Study of BMS-986218 Alone or in Combination with Nivolumab for Male Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Karie D. Runcie, MD
Prostate Cancer Study of XmAb20717 Alone or in Combination with Chemotherapy in Patients with Prostate Cancer Mark Stein, MD
Prostate Cancer Study of Cabozantinib in Patients with Prostate Cancer who Previously Received Anti-Androgen Therapy Mark Stein, MD
Kidney Cancer Study of Experimental Drug (Axitinib) in Patients with Metastatic Pheochromocytoma (PCC) or Paraganglioma Antonio Fojo, MD, PhD
Kidney Cancer Study of Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients with Localized Clear Cell Renal Cell Carcinoma Karie D. Runcie, MD
Kidney Cancer Cyto-KIK Trial: CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition Mark Stein, MD
Sarcoma A Study for Patients with Malignant Peripheral Nerve Sheath Tumors Using Study Drugs PLX3397 and Sirolimus Gulam Manji, MD, PhD
Sarcoma A Study of the Addition of APX005M to Doxorubicin in Patients with Advanced Sarcoma Matthew Ingham, MD
Sarcoma A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) Matthew Ingham, MD
Sarcoma Study of Paclitaxel With and Without Nivolumab and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma Gary Schwartz, MD
Sarcoma Study of Belinostat and Guadecitabine for Treatment of Chondrosarcoma Matthew Ingham, MD
Sarcoma Study of Envafolimab in Patients with Sarcoma or Myxofibrosarcoma Gary Schwartz, MD
Sarcoma A Study of AL102 in Patients With Progressing Desmoid Tumors (RINGSIDE) Gary Schwartz, MD
Sarcoma Study of Milademetan in Comparison to Trabectedin in Patients with Liposarcoma Gary Schwartz, MD
Sarcoma Study of ATX-101 in Patients with Dedifferentiated Liposarcoma (LPS) and Leiomyosarcoma (LMS) Matthew Ingham, MD
Sarcoma Study of INBRX 109 in Patients with Metastatic or Inoperable Chondrosarcoma Matthew Ingham, MD
Sarcoma Study of AGEN1181 Alone or in Combination with Balstilimab in Patients with Advanced Sarcoma Gary Schwartz, MD
Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Richard Carvajal, MD
Brain Cancer Study of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma Andrew Lassman, MD
Brain Cancer Study to Evaluate Multiple Treatments for Patients with Newly Diagnosed or Recurrent GBM Andrew Lassman, MD
Brain Cancer Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) Andrew Lassman, MD
Brain Cancer A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Andrew Lassman, MD
Brain Cancer Study of Tumor Treating Fields (Optune, 200kHz) with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Fabio Iwamoto, MD
Brain Cancer Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary Central Nervous System (CNS) Lymphoma Aya Haggiagi, MD
Brain Cancer Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects Fabio Iwamoto, MD
Brain Cancer ImmuneSense Study: IGV-001 in Newly Diagnosed Patients With Glioblastoma Fabio Iwamoto, MD
Brain Cancer Study of Vismodegib and GSK2256098 to Shrink Tumors in Patients with Meningioma Mary Welch, MD
Brain Cancer Study of Chemotherapy Drug, Lomustine, in Addition to Temozolomide in Patients with Glioblastoma (GBM) Fabio Iwamoto, MD
Brain Cancer Study of Immune Therapy Drugs in Addition to the Usual Radiation Therapy for Patients with Brain Cancer (Glioblastoma) Fabio Iwamoto, MD
Brain Cancer Study of Vaccine for Cytomegalovirus (CMV) in Patients with Brain Tumor Andrew Lassman, MD
Brain Tumors Study of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma Andrew Lassman, MD
Brain Tumors Study to Evaluate Multiple Treatments for Patients with Newly Diagnosed or Recurrent GBM Andrew Lassman, MD
Childhood Leukemia Study of Nivolumab in Combination with 5-Azacytidine in Acute Myeloid Leukemia (AML) - Children and Adults Age 1 to 30 Nobuko Hijiya, MD
COVID-19 (Coronavirus) COVID-19 Biobank: For People Who Have Been Tested for COVID-19 at NewYork-Presbyterian Hospital Muredach Reilly, MD
COVID-19 (Coronavirus) Multiple Sclerosis (MS) Patient Response to COVID-19 Outbreak: Recruiting Participants with and without MS Philip De Jager, PhD
Brain Tumors Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) Andrew Lassman, MD
Brain Tumors A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Andrew Lassman, MD
Brain Tumors Study of Tumor Treating Fields (Optune, 200kHz) with Radiation Therapy and Temozolomide for Treatment of Newly Diagnosed Glioblastoma Fabio Iwamoto, MD
Squamous Cell Carcinoma Study of Ruxolitinib in Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma Richard Carvajal, MD
Brain Tumors Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary Central Nervous System (CNS) Lymphoma Aya Haggiagi, MD
Melanoma CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma Benjamin Izar, MD
Autoimmune Disorders Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Brian Henick, MD
Brain Tumors Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects Fabio Iwamoto, MD
Brain Tumors ImmuneSense Study: IGV-001 in Newly Diagnosed Patients With Glioblastoma Fabio Iwamoto, MD
Melanoma Study of SD-101 in Patients with Metastatic Uveal Melanoma (Eye Cancer) with Liver Disease Shaheer Khan, DO
Brain Tumors Study of Vismodegib and GSK2256098 to Shrink Tumors in Patients with Meningioma Mary Welch, MD
Obstetrics & Gynecology Study of Pembrolizumab in Combination with Chemotherapy for Patients with Endometrial Cancer Jason Wright, MD
Melanoma A First-in-Human Study Using FHD-286 in Patients with Metastatic Uveal Melanoma Richard Carvajal, MD
Cancer Study of MTX110 in Combination with Gadolinium in Children with Newly Diagnosed Brain Cancer (Diffuse Midline Gliomas) Luca Szalontay, MD
Depression Tele-IPT vs. Tele-Pharmacotherapy for Depression in Patients with Non-Metastatic Breast Cancer John Markowitz, MD
Brain Tumors Study of Chemotherapy Drug, Lomustine, in Addition to Temozolomide in Patients with Glioblastoma (GBM) Fabio Iwamoto, MD
Melanoma Study of ALKS 4230 in Patients with Previously Treated Advanced Melanoma Benjamin Izar, MD
Brain Tumors Study of Immune Therapy Drugs in Addition to the Usual Radiation Therapy for Patients with Brain Cancer (Glioblastoma) Fabio Iwamoto, MD
Cancer Study of Olanzapine in Children Receiving Chemotherapy for Hematopoietic Stem Cell Transplant (HSCT) Diane George, MD